FDA Clears Chewable Methylphenidate (QuilliChew) for ADHDFDA Clears Chewable Methylphenidate (QuilliChew) for ADHD

QuilliChew extended-release (Pfizer) is for treatment of attention-deficit/hyperactivity disorder (ADHD) in children aged 6 years and older. FDA Approvals
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry News Alert Source Type: news

Related Links:

ConclusionsThe DCE was sensitive to caregivers’ preferences for managing their child's coexisting cognitive/intellectual and emotional/behavior/developmental disability. Findings may help providers gauge treatment in a broader context of health outcomes.
Source: Academic Pediatrics - Category: Pediatrics Source Type: research
The aim of our study was to investigate the relationship between child abuse and emotional and behavioral problems in Chinese school-aged boys with attention deficit hyperactivity disorder (ADHD). Forty-eight school-aged boys with ADHD and 77 male healthy ...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
OBJECTIVE: Our objective was to determine whether ADHD medication is associated with a decreased risk of unintentional injuries in children and adolescents in the United States across sexes, age groups and injury types. METHOD: We used de-identifie...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
This study aims to examine the association between early gestational maternal C-reactive protein (CRP), prospectively assayed in stored maternal sera and the risk of ADHD in offspring. This study is based on the Finnish Prenatal studies of ADHD (FIPS-ADHD) with a nested case –control design. It includes all singleton-born children in Finland between January 1, 1998 and December 31, 1999 and diagnosed with ADHD. A total of 1079 cases and equal number of controls were matched on date of birth, sex and place of birth. Maternal CRP levels were assessed using a latex immun oassay from archived maternal serum specimens, co...
Source: European Child and Adolescent Psychiatry - Category: Psychiatry Source Type: research
Conclusion Consumption showed an increase in use of methylphenidate in South Africa, with small changes observed over the study period. Further studies are required.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
Condition:   Attention Deficit Hyperactivity Disorder in Adults Intervention:   Other: questionnaires Sponsor:   University Hospital, Strasbourg, France Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
To the Editor In their cohort study, Brander et al observed an increased risk of metabolic and cardiovascular diseases in patients with Tourette syndrome (TS) and chronic tic disorder. This risk was even higher in patients with comorbid attention-deficit/hyperactivity disorder. Interestingly, metabolic and cardiovascular risks were already present at an early stage of the disorder and were actually decreased in patients that used antipsychotic medication for a longer time. These data are relevant for the field because they were previously unknown in this form and must be considered in the future care of these patients.
Source: JAMA Neurology - Category: Neurology Source Type: research
Abstract Attention-deficit/hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder and is characterized by symptoms of inattention and/or hyperactivity and impulsivity. In the current study, we obtained quantitative EEG (QEEG) recordings of 51 children aged between 6 and 12 years before the initiation of methylphenidate treatment. The relationship between changes in the scores of ADHD symptoms and initial QEEG features (power/power ratios values) were assessed. In addition, the children were classified as responder and nonresponder according to the ratio of their response to the medication (&g...
Source: Clinical EEG and Neuroscience - Category: Neuroscience Authors: Tags: Clin EEG Neurosci Source Type: research
CONCLUSIONS: Suicidal risks were high in mood disorders: ideation was highest with BD type II, attempts and suicides (especially violent) with BD type I. Several risk factors for suicidal acts differed between BD versus MDD patients.Declaration of interestNo author or immediate family member has financial relationships with commercial entities that might appear to represent potential conflicts of interest with the information presented. PMID: 31292010 [PubMed - as supplied by publisher]
Source: The British Journal of Psychiatry for Mental Science - Category: Psychiatry Tags: Br J Psychiatry Source Type: research
Publication date: September 2019Source: Research in Developmental Disabilities, Volume 92Author(s): Guillaume Pineau, Thomas Villemonteix, Hichem Slama, Martin Kavec, Danielle Balériaux, Thierry Metens, Simon Baijot, Alison Mary, Nicolas Ramoz, Philip Gorwood, Philippe Peigneux, Isabelle MassatAbstractDopamine active transporter gene (DAT1) is a candidate gene associated with attention-deficit/hyperactivity disorder (ADHD). The DAT1 variable number tandem repeat (VNTR)-3’ polymorphism is functional and 9R carriers have been shown to produce more DAT than 10R homozygotes. We used functional magnetic resonance i...
Source: Research in Developmental Disabilities - Category: Disability Source Type: research
More News: ADHD | Children | Concerta | Hyperactivity | Methylphenidate | Pfizer | Psychiatry | Ritalin